EyePoint advances with Duravyu Phase III trial
EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for LUGANO, its pivotal Phase III clinical trial.
EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for LUGANO, its pivotal Phase III clinical trial.
What's Your Reaction?
